Latest Form 4 insider transactions

Michael H Thaman, a Director of Sherwin Williams Co, received 104 shares of common stock on October 2, 2026.

Robert James Gamgort, a Director of Sherwin Williams Co, received 104 shares of common stock on October 2, 2026.

Andrew E. Singer, a Director of Fibrogen Inc, received 14,000 shares of common stock on October 1, 2026.

Kerrii B Anderson, a Director of Sherwin Williams Co, received 31 shares of common stock on October 2, 2026.

Cheryl Cohen, a Director of ImmunityBio, Inc., sold 81,056 shares of common stock on October 2, 2026 for $10.50 per share.

Ryan Israel, Chief Investment Officer of Pershing Square USA, Ltd., purchased 256,613 shares of common stock on October 2, 2026.

Peter Greenleaf, a Director of Channel Therapeutics Corp, sold 797 shares of common stock on October 2, 2026 for $21.17 per share.

Ezra M Friedberg, a Director of Channel Therapeutics Corp, sold 558 shares of common stock on October 2, 2026 for $20.72 per share.

Matthew Pauls, a Director of Channel Therapeutics Corp, sold 786 shares of common stock on October 2, 2026 for $21.00 per share.

Kenneth W Lowe, a Director of Warner Bros. Discovery, Inc., reported multiple transactions in common stock on October 6, 2026.

Daniel E. Sanchez, a Director of Warner Bros. Discovery, Inc., reported multiple transactions in common stock on October 6, 2026.

Paula A Price, a Director of Warner Bros. Discovery, Inc., reported multiple transactions in common stock on October 6, 2026.

Richard W Fisher, a Director of Warner Bros. Discovery, Inc., reported multiple transactions in common stock on October 6, 2026.

Paul A Gould, a Director of Warner Bros. Discovery, Inc., reported multiple transactions in common stock on October 6, 2026.

Sheela Kosaraju, EVP & Chief Legal Officer of Ciena Corp, sold 2,101 shares of common stock on October 1, 2026 for $355.19 per share.

Olivia Nottebohm, Chief Operating Officer of Box Inc, sold 5,293 shares of common stock on October 5, 2026 for $34.50 per share.

Yvonne Wassenaar, a Director of Rubrik, Inc., sold 721 shares of common stock on October 5, 2026 for $119.00 per share.

Douglas M. Schafer Jr, EVP and CIO of Miami International Holdings, Inc., sold 40,000 shares of common stock on October 2, 2026 for $33.34 per share.

Jason Phipps, EVP & Chief Customer Officer of Ciena Corp, sold 2,629 shares of common stock on October 1, 2026 for $355.19 per share.

William Joseph Brennan, Pres & Chief Executive Officer and a Director of Credo Technology Group Holding Ltd, reported multiple transactions in common stock on October 2, 2026.

C.H. Robinson's CEO introduces RXO's integration, emphasizing complementary strengths and a shared vision for enhanced supply chain solutions and long-term growth.

Daniel W. Fleming, Chief Financial Officer of Credo Technology Group Holding Ltd, reported multiple transactions in common stock on October 2, 2026.

C.H. Robinson's CEO introduces RXO's integration, emphasizing complementary strengths and a shared vision for enhanced supply chain solutions and long-term growth.

Ctt Pharmaceutical Holdings, Inc. reported changes in beneficial ownership of Ctt Pharmaceutical Holdings, Inc. common stock on October 1, 2026.

QuasarEdge Acquisition Corporation has entered into a First Amendment to its Agreement and Plan of Merger with Robseek Intelligence Inc., clarifying terms related to share structures, rights, and lock-up provisions.

Elena Marquez, Chief Financial Officer of Anterix Inc., reported a transaction in 473 shares of common stock on October 5, 2026.

Sean Patrick Duffy, SVP, Finance & Accounting(PAO) of Insperity, Inc., reported multiple transactions in common stock on October 5, 2026.

William Holmes Heissenbuttel, President & CEO and a Director of Royal Gold Inc, sold 2,425 shares of common stock on October 5, 2026.

C.H. Robinson CEO Dave Bozeman expresses excitement about RXO joining forces, emphasizing complementary strengths and a shared commitment to customer service and innovation.

RXO, Inc. and C.H. Robinson leadership communicate updates regarding their proposed transaction, emphasizing continued business operations and strategic alignment.